TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: MOnitoring REsynchronization deviCes and cARdiac patiEnts

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient indicated to CRT-ICD according to current guidelines:~* Left ventricular systolic dysfunction (LVEF≤35%),~* New York Heart Association functional class III-IV,~* QRS≥120 ms~* Optimized medical treatment.~* Patient implanted within the last 8 weeks with Medtronic CRT-ICD device equipped with fluid accumulation diagnostics, AT/AF monitoring capability, wireless telemetry for automatic remote data transmission and alerting system for physician.~* Patient with less than 8 weeks follow-up, who has not received Carelink® Network Monitor and was not managed by Cardiac Compass report reviewing.~* Carelink Network is available at patient's home~* Patient or the patient's caregiver is willing and able to use the Medtronic CareLink® Network Monitor and to perform the required duties at home or has a family member or assistant perform those duties.~* Patient is willing and able to sign an informed consent form.~Exclusion Criteria:~* Inability to fully understand the instructions relating to remote monitoring using CareLink® Network.~* Permanent AT/AF.~* Patient had not been previously implanted with a CRT/CRT-D device.~* Patient has medical conditions that would limit study participation.~* Patient is less than 18 years of age.~* Patient is enrolled in or intends to participate in another clinical trial that may have an impact on the study endpoints.~* Patient meets any exclusion criteria required by local law.~* Inability or refusal to sign a patient informed consent form.~* Patient's life expectancy is less than one year in the opinion of the physician~* Patient is pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Study Group (Type: ACTIVE_COMPARATOR): Patients of the study arm are CRT-D patients followed-up by means of a remote disease management system (Medtronic Carelink® Network), for which an automatic alerting system is enabled for fluid accumulation, AT/AF episodes and system integrity.
- Control Group (Type: NO_INTERVENTION): Patients are CRT-D patients managed according to current standard clinical practice, based on routinely performed in-office visits.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Gemcitabine and Abraxane for Pancreas Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed metastatic adenocarcinoma of the pancreas~* Progression on first line non-gemcitabine based therapy for metastatic or relapsed disease~* Radiographically measurable or evaluable disease~* Age \>/= 18 years~* ECOG performance status 0-2~* Adequate hepatic, bone marrow and renal function~Exclusion Criteria:~* Prior gemcitabine-based chemotherapy in the first line setting~* No active severe infection, or known chronic infection with HIV or hepatitis B virus~* No cardiovascular disease problems including unstable angina, therapy for life-threatening ventricular arrhythmia, or myocardial infarction, stroke, or congestive heart failure within the last 6 months~* No women who are pregnant or breastfeeding, and no women of childbearing potential without using dual forms of contraception~* Patients with known CNS metastases~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine or nab-paclitaxel~* Anticipated patient survival under 2 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gemcitabine/abraxane (Type: EXPERIMENTAL): Gemcitabine and Abraxane

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Hysterectomy After Chemoradiation Therapy for Stage IB2/II Cervical Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* operable Stage IB2/II Cervical Cancer~* adenocarcinoma, squamous cell or adenosquamous carcinoma~* Patient between 18 and 70 years old~* No lombo-aortic lymph node invasion at baseline~* Previous 45 grays external pelvic radiation with concomitant chemotherapy (cisplatin 40 mg/m2/week corresponding to 5 cycles)~* Followed by a 15 grays utero-vaginal brachytherapy, eventually combined with a 6th cycle of chemotherapy (cisplatin 40 mg/m2)~* with a pelvic boost if lymph node or parametrial invasion~* No macroscopic residual tumor after 6 to 8 weeks after brachytherapy.~Exclusion Criteria:~* Other tumor histology (neuro-endocrine)~* Stage \> II (FIGO 1995) at baseline~* Patient with remaining cervical cancer (after sub-total hysterectomy)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- with hysterectomy (Type: EXPERIMENTAL): None
- without hysterectomy (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Evaluation of Multi-modality Algorithm for Non-metastatic Adenocarcinoma of Pancreas or Ampulla

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic proof of adenocarcinoma consistent with ductal carcinoma of pancreas or ampulla, with no evidence of metastatic disease by clinical exam or cross-sectional imaging.~* Fitness for chemotherapy in judgement of treating physician~* Bilirubin \< 4 (any means of biliary drainage acceptable)~Exclusion Criteria:~* Medical or mental illness precluding provision of informed consent~* Pregnancy~* Active infection for which neutropenia would pose high risk of mortality

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Resectable, Low Risk (Type: EXPERIMENTAL): Systemic chemotherapy followed by definitive surgery without pre-operative or post-operative radiotherapy.
- Locally Advanced (Type: EXPERIMENTAL): Systemic chemotherapy followed by chemoradiation, followed by definitive surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Acute Sinusitis With High-Dose vs. Standard-Dose Amoxicillin/Clavulanate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults 18 and older who are patients at the Albany Medical Center Internal Medicine and Pediatrics practice (study site).~2. Clinical diagnosis of acute bacterial sinusitis in accordance with the guidelines of the Infectious Disease Society of America (fitting into one of 3 categories: persistent sinus symptoms for 10 days or more; severe sinus symptoms for 3 days or more; or worsening sinus symptoms after initial improvement (double sickening).~Exclusion Criteria:~1. Previous enrollment in the current study~2. Allergy or intolerance to any penicillin or to amoxicillin/clavulanate~3. Serious hypersensitivity reaction to any beta lactam~4. Elevated risk of amoxicillin-resistant bacteria: a. amoxicillin, penicillin, or other beta-lactam within the past month; b. known to have had methicillin-resistant Staph aureus~5. Chronic or recurrent sinus problems (defined as a) persistent symptoms of sinus congestion, not attributed to nasal allergies, for 8 weeks or more or b) 2 or more episodes of antibiotic-treated sinusitis in past 3 months~6. Need to use high-dose amoxicillin/clavulanate or levofloxacin or to send to emergency department or to hospitalize because of a) signs of severe infection or b) immunocompromise~7. Cognitive impairment, so unable to give reliable symptom ratings (even if a health proxy can give consent)~8. Pregnant women and nursing mothers~9. Drug warnings: a) taking allopurinol; b) current mononucleosis; c) chronic kidney disease stage 4 (estimated glomerular filtration rate \<30); d) hepatic impairment (not including isolated transaminase elevated \< 2 times upper limit of normal); e) history of antibiotic-associated colitis (C. difficile)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- High dose (Type: EXPERIMENTAL): Amoxicillin/clavulanate 875mg/125mg \& amoxicillin 875 mg twice a day x 7 days
- Standard dose (Type: ACTIVE_COMPARATOR): Amoxicillin/clavulanate 875 mg/125mg \& placebo (lactase) twice a day x 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have systemic signs and symptoms of inflammation as manifested NNS/CANDLE, SAVI, AGS~* Have been diagnosed with genetic diagnosis~* Men must agree to use a reliable method of birth control during the study~* Women not of child-bearing potential or nonbreastfeeding~* Women must agree to use birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment~* NNS/CANDLE and SAVI patients who are ≥17.5 months of age~* AGS patients who are ≥6 months of age~* Are ≥ 5kg in body weight~Exclusion Criteria:~* Have received immunosuppressive biologic agent/monoclonal antibody/oral JAK inhibitor/OAT3 inhibitor and cannot discontinue prior to investigational product initiation. Note: A washout period is required to each drug.~* Have diagnosis of current active tuberculosis (TB) or, latent TB who did not receive appropriate treatment.~* Have had a serious infection within 12 weeks prior to screening.~* Have a history of lymphoproliferative disease~* Have any history of venous thromboembolic event (VTE) (deep vein thrombosis \[DVT\]/pulmonary embolism \[PE\]) prior to screening.~* Have had any major surgery within 8 weeks prior to screening.~* Have previously been enrolled in any other study investigating baricitinib.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Baricitinib (Type: EXPERIMENTAL): CANDLE:~Participants with chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) received an optimized dosage of baricitinib that was determined throughout the dose-adjustment period administered as tablets or oral suspension based on participants weight and estimated glomerular filtration rate (eGFR).~SAVI:~Participants with STING-associated vasculopathy with onset during infancy (SAVI) received an optimized dosage of baricitinib that was determined throughout the dose-adjustment period administered as tablets or oral suspension based on participants weight and estimated glomerular filtration rate (eGFR).~Aicardi-Goutières Syndrome (AGS):~Participants with Aicardi-Goutières Syndrome (AGS) received an optimized dosage of baricitinib that was determined throughout the dose-adjustment period administered as tablets or oral suspension based on participants weight and estimated glomerular filtration rate (eGFR).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Transcranial Direct Current Stimulation for Post-Stroke Aphasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age over 21 years~2. Ischemic left hemispheric stroke verified by imaging (CT or MRI) greater than 6 months ago~3. Residual non-fluent or anomic aphasia, with Western Aphasia Battery-Revised Aphasia Quotient score \<60~4. Fluent English speaker prior to stroke~5. Right-handed prior to stroke~6. Ability to give informed consent and understand the tasks involved.~Exclusion Criteria:~1. History of recurrent stroke, either ischemic or hemorrhagic, in the left middle cerebral artery territory~2. Imaging unavailable~3. Large middle cerebral artery infarct involving entire inferior division (temporo-parietal) territory~4. History of dementia prior to the stroke~5. History of seizure, prior electroconvulsive therapy, deep brain stimulators, or brain surgery~6. Social and/or personal circumstances that interfere with ability to return for therapy and assessment sessions.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anodal tDCS (Type: EXPERIMENTAL): Anodal tDCS over the left posterior language areas during aphasia therapy for 8 one-hour sessions
- Sham tDCS (Type: SHAM_COMPARATOR): Sham tDCS over the left posterior language areas during aphasia therapy for 8 one-hour sessions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Whole Blood Metal Ion Concentrations in Metal-on-metal Total Hip Arthroplasty and Hip Resurfacing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Primary or secondary hip osteoarthritis eligible for hip replacement surgery~* Able to give informed consent~* Able to complete follow up consultations~Exclusion Criteria:~* Earlier or present infection of the hip~* Severe systemic or metabolic disease leading to weakening of the bone~* Severe congenital hip dysplasia~* Osteoporosis and/or renal disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Magnum (Type: ACTIVE_COMPARATOR): A metal-on-metal large diameter head total hip arthroplasty
- Recap (Type: ACTIVE_COMPARATOR): A metal-on-metal hip resurfacing arthroplasty

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Consumer Engagement to Increase Advance Care Planning

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
PCP Subject Inclusion Criteria:~* Partnership HealthPlan of California Medicaid and/or Medicare provider~PCP Subject Exclusion Criteria:~* Prohibition by clinic director~Patient Subject Inclusion Criteria:~* Partnership HealthPlan of California Medicaid and/or Medicare enrollee;~* Age 65+ or \< 65 with a life-limiting illness (including advanced cardiac disease \[end-stage congestive heart failure, severe coronary artery disease, cardiomyopathy (LVEF \<25%)\], advanced chronic obstructive pulmonary disease, amputation due to vascular disease, cancer \[metastatic/recurrent\], dementia, diabetes mellitus with creatinine clearance under 50, or an amputation, end stage renal disease, generalized debility and decreased functioning, long term resident of skilled nursing facility, stroke \[w/at least 50% decreased function\]);~* Internet access (computer, tablet, phone)~Patient Subject Exclusion Criteria:~* Completion of a Partnership HelathPlan of California advance care planning attestation form within the last 12 months;~* Inability to read English

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PREPARE (Type: ACTIVE_COMPARATOR): Partnership HealthPlan of California (PHC) pays primary care physicians (PCPs) to discuss and document ACP with Medi-Cal beneficiaries aged 65 and older and those younger than 65 with a life-limiting illness (usual care). The control condition, or enhanced usual care, adds a packet of educational information about ACP and access to the PREPARE website and verbal encouragement by their PCP delivered during a routine clinic visit to usual care.
- PREPARE + consumer financial incentive (Type: EXPERIMENTAL): The experimental condition adds a consumer-directed financial incentive to enhanced usual care (provider-directed financial incentive and educational packet with information about the PREPARE website). Specifically, subjects will receive an immediate financial reward upon completing self-directed ACP (e.g., PREPARE steps 1-4) and a small probability of a large reward for discussing the plans with their physician (e.g., PREPARE step 5, documented by the PHC ACP attestation form).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Tolerance of Three Doses of G17DT in Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18 years or over with histologically verified adenocarcinoma of colon or rectum.~* Recurrent of metastatic disease not amenable to curative surgery and/or radiotherapy.~* Life expectancy greater than 3 months.~* Karnofsky Index Score greater than or equal to 50%.~* Written informed consent obtained.~Exclusion Criteria:~* Neoplastic lesions other than colorectal cancer (except treated basal cell carcinoma of the skin or cancer of the uterine cervix, through Stage I.~* Acute intercurrent illness.~* Patient considered to be a medical risk because of non-malignant systemic disease or grossly abnormal laboratory results.~* Patients who had received any other anticancer therapy within 3 months.~* Factor liable to alter the serum gastrin concentration or affect intra-gastric acidity, for instance concomitant therapy with H2 receptor antagonist drugs, proton pump inhibitors, or previous gastric surgery.~* Patients immunologically compromised including those on corticosteroid therapy.~* Women of child-bearing age.~* Positive immediate hypersensitivity reaction to skin testing with study medication.~* Patients unable to complete the diary book~* Haematogical Status Haemoglobin count less than 10g/dL White Blood Cell count less than 4.0 x 10\^9/L Platelet count less than 100 x 10\^9/L

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 100µg dose of G17DT (Type: EXPERIMENTAL): Patients in this arm received a 100µg dose of G17DT via intramuscular injection.
- 200µg dose of G17DT (Type: EXPERIMENTAL): Patients in this arm received a 200 µg dose of G17DT via intramuscular injection.
- 500µg dose of G17DT (Type: EXPERIMENTAL): Patients in this arm received a 500µg dose of G17DT via intramuscular injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: HEAD-Study Optimizing the Treatment of Children With BECTS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Age between 6 and 12 years~2. Weight between 15 kg and 60 kg~3. At least two preceding seizures within the last six months before study start~4. Typical electroencephalogram (EEG) with Rolando focus (centrotemporal spike or sharp-wave-focus)~5. Diagnosis of BECTS~6. Written informed consent from parents and child~Exclusion Criteria:~1. Other forms of epilepsy (e.g. continuous spikes and waves during slow sleep \[CSWS\], Landau-Kleffner-syndrome)~2. Preceding treatment with antiepileptic drugs~3. Mental Retardation (intelligence quotient \[IQ\] \<85)~4. Focal neurological deficit~5. Relevant major internistic disease (e.g. hepatopathy, nephropathy, endocrinopathy)~6. Participation in another clinical trial within the last 30 days

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues